Table 5. Outcomes in Old World leishmaniasis studies.
| Year, Author | Study arms (number of patients) | Epithelialization rate between 30–73 days, number of patients (%) | Epithelialization rate between 74–100 days, number of patients (%) | Epithelialization rate between 101–194 days, number of patients (%) | Follow-up lost | Relapse after cure /n |
|---|---|---|---|---|---|---|
| 2016, Jaffary | MA-IL (30) | 10 (38.5) | - | - | 14/90 | 0/76 |
| MA-IL + TCA (30) | 27 (90) | |||||
| MA-IL + CO2 (30) | 27 (90) | |||||
| 2016, Rajabi | Azithro (26) | 20/26 (77.8) | - | - | 2/66 | 0/64 |
| MA-IL (40) | 30/40 (76.3) | |||||
| 2016, Yesilova | MA-IL (1728) | 1668/1728 (96.5) | - | - | - | NR |
| SSG-IL (1728) | 1574/1728 (90.5) | |||||
| 2015, Ranawaka | SSG-IL (170) | 158/170 (92.9) | - | - | 6/170 | 0/427 |
| 10% HS (192) | 178/192 (89.1) | 8/192 | ||||
| 15% HS (82) | 74/82 (90.2) | 3/82 | ||||
| 2014, Refai | RFHT (98) | 57/98 (58.5) | 69/98 (70.5) | - | NR | NR |
| SSG-IL (115) | 60/115 (52.3) | 81/115 (70.5) | ||||
| 2014, Stahl | SSG-IL (24) | 15/24 (62.5) | - | - | 1/24 | NR |
| MWT DAC N-055 (29) | 23/29 (79.3) | 6/29 | ||||
| HF-EC/MWT DAC N-055 (28) | 20/28 (71.4) | 5/28 | ||||
| 2014, Agrawal | SSG-IL (58) | 49/58 (84.4) | - | - | 9/148 | NR |
| RFHT (14) | 13/14 (91.8) | |||||
| Rifampicin (50) | 41/50 (82) | |||||
| Dapsone (3) | 2/3 (66.7) | |||||
| Rifampicin + SSG-IL (12) | 11/12 (90.1) | |||||
| Dapsone+ Rifampicin (11) | 10/11 (90.1) | |||||
| 2014, Solomon | SSG-IL (21) | - | 14/21 (66.6) | - | 0/45 | 0/45 |
| L-AmB-IV (24) | 18/24 (75) | |||||
| 2014, Nilforoushzadeh | MA-IL (100) | 76/100 (76) | - | - | 4/100 | NR |
| MA-IL + TCA (100) | 78/100 (78) | 9/100 | ||||
| 2013, Mohammadzadeh | MA-IL (38) | 31/38 (81.6) | - | - | 18/155 | NR |
| MA-IM (94) | 72/94 (75.8) | |||||
| MA-IL + MA-IM (4) | 4/4 (100) | |||||
| 2013, Bumb | RFHT (50) | 25/50 (50) | 49/50 (98) | 49/50 (98) | 0/50 | 0/50 |
| SSG-IL (50) | 28/50 (56) | 43/50 (93) | 47/50 (94) | 0/50 | 0/50 | |
| 2012, Maleki | ZnSO4 (24) | 8/24 (33.3) | - | - | 11/45 | NR |
| MA-IL (10) | 8/10 (80) | |||||
| 2012, Nilforoushzadeh | MA-IL (30) | - | - | 24/30 (63.2) | 0/60 | NR |
| RFHT + TCA (30) | 16/30 (42.1) | |||||
| 2012, Safi | RFHT (189) | - | - | 143/193 (74) | NR | NR |
| MA-IL (193) | 156/189 (82.5) | |||||
| 2011, Layegh | L- AmB (50) | - | - | 22/50 (44) | NR | NR |
| MA-IL (60) | 29/60 (48.3) | |||||
| 2010, van Thiel | SSG-IL (118) | - | - | 65/118 (55.1) | NR | 18/118 |
| SSG-IL + Cryo (45) | 30/45 (66.7) | 5/45 | ||||
| 2010, Bumb | SSG-IL 1x/w (110) | 68/110 (62) | - | 101/110 (92) | 22/220 | 0/220 |
| SSG-IL 2x/w (110) | 80/110 (73) | 106/110 (96) | ||||
| 2010, Ranawaka | SSG-IL (87) | - | 87/87 (100) | NR | NR | 0/154 |
| 7% HS (67) | 62/67 (92.2) | |||||
| 2009, Solomon | SSG-IL (33) | - | 30/33 (91) | - | 0/54 | NR |
| SSG-IV (21) | 18/21 (86) | |||||
| 2009, Layegh | MA-IL (39) | - | - | 10/39 (25%) | 3/39 | NR |
| Cryo (40) | 31/40 (52.5) | 3/40 | ||||
| 2008, Qasmi | MA-IL (13) | 8/13 (61.5) | - | - | 1/13 | 0/13 |
| 2007, Nilforoushzadeh | MA-IL + honey (45) | 32/45 (71.1) | - | 32/45 (71.1) | 10t/90 | NR |
| MA-IL (45) | 23/45 (51.1) | 24/45 (52) | ||||
| 2007, Sadeghian | RFHT (57) | 46/57 (80.7) | - | - | 0/117 | 0/117 |
| MA-IL (60) | 34/60 (56.7) | |||||
| 2006, Nilforoushzadeh | MA-IL (40) | 23/40 (57.5) | - | - | 5/40 | 4/35 |
| TCA (40) | 26/40 (65) | 2/40 | 5/38 | |||
| 2006, Salmanpour | MA-IL (20) | 15/20 (75) | - | - | NR | NR |
| Cryo (20) | 13/20 (67.8) | |||||
| Cryo + MA-IL (20) | 18/20 (89) | |||||
| 2005, Sadeghian | HS (36) | 9/36 (25) | - | 9/36 (25) | 1/36 | NR |
| MA-IL (36) | 15/36 (52) | 15/36 (52) | ||||
| 2005, Shazad | Paro (30) | 20/29 (69) | - | - | 1/30 | 0/56 |
| MA-IL (30) | 8/27 (67) | 3/30 | ||||
| 2003, Nilforoushzadeh | TCA (38) | 26/38 (68) | - | - | 7/80 | NR |
| MA-IL (35) | 23/35 (65.7) | |||||
| 2003, Faghihi | Paro (48) | 8/48 (16.6) | - | - | 0/96 | NR |
| MA-IL (48) | 20/48 (41.7) | |||||
| 2001, Salmanpour | Keto (64) | 57/64 (89) | - | - | 0/96 | NR |
| MA-IL (32) | 23/32 (72) | |||||
| 1999, Chahed | MA-IL (52) | 22/52 (41.7) | 43/52 (83.3) | - | NR | NR |
| Eosine (57) | 24/57 (41.7) | 47/57 (83.3) | ||||
| 1990, el Darouti | Cryo + MA-IL (15) | 15/15 (100) | - | - | 0/44 | NR |
| Cryo (14) | 11/15 (68) | |||||
| SSG-IL (15) | 6/15 (44) | |||||
| 1979, Ghosn | SSG-IL (16) | 11/16 (68.7) | - | - | NR | NR |
| SSG-IM (12) | 12/12 (100) |
NR: no reported Azithro: Azitromycin Cryo: Cryotherapy CO2:Carbon Dioxide Laser HS: intralesional hypertonic saline Keto: Ketoconazole Paro: Paromomycin L-AmB-IL: intralesional liposomal amphotericin B MA-IL: intralesional meglumine antimoniate MA-IM: intramuscular meglumine antimoniate MWT DAC N-055: moist wound treatment (MWT)with 0.045% pharmaceutical sodiumchlorite solution(DAC N-055) RFHT: radiofrequency heat therapy RFHT/MWT DAC N-055: high-frequency(HF)-electro-cauterization (EC) combined with subsequent moist wound treatment (MWT) with 0.045% pharmaceutical sodium chlorite solution SSG-IL: intralesional sodium stibogluconate TCA: topical trichloroacetic acid ZnSO4: intralesional zinc sulfate